| 51.96 -0.15 (-0.29%) | 06-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 62.46 | 1-year : | 72.95 |
| Resists | First : | 53.47 | Second : | 62.46 |
| Pivot price | 48.59 |
|||
| Supports | First : | 48.42 | Second : | 45.29 |
| MAs | MA(5) : | 51.09 |
MA(20) : | 49.06 |
| MA(100) : | 55.25 |
MA(250) : | 46.05 |
|
| MACD | MACD : | -0.4 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 79.9 |
D(3) : | 77.8 |
| RSI | RSI(14): 56  |
|||
| 52-week | High : | 65 | Low : | 29.07 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PCVX ] has closed below upper band by 9.4%. Bollinger Bands are 6.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 53.36 - 53.63 | 53.63 - 53.84 |
| Low: | 50.86 - 51.15 | 51.15 - 51.36 |
| Close: | 51.51 - 51.99 | 51.99 - 52.35 |
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Tue, 23 Jun 2026
Moncef Slaoui gets 26,061 Vaxcyte (PCVX) options at $52.11 strike - Stock Titan
Tue, 23 Jun 2026
Vaxcyte (PCVX) director Moncef Slaoui files Form 3 reporting zero share ownership - Stock Titan
Tue, 23 Jun 2026
Moncef Slaoui joins Vaxcyte (NASDAQ: PCVX) board as director - Stock Titan
Mon, 22 Jun 2026
Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine - Yahoo Finance
Mon, 22 Jun 2026
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring The 111.90% Potential Upside For Investors - DirectorsTalk Interviews
Thu, 18 Jun 2026
Vaxcyte (PCVX) CFO sells 10K shares under 10b5-1 plan, holds 166K+ - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 144 (M) |
| Shares Float | 132 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 114.6 (%) |
| Shares Short | 14,470 (K) |
| Shares Short P.Month | 14,140 (K) |
| EPS | -6.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.3 % |
| Return on Equity (ttm) | -30.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -770 (M) |
| Levered Free Cash Flow | -440 (M) |
| PE Ratio | -7.55 |
| PEG Ratio | 0 |
| Price to Book value | 2.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|